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An inherent problem to the Valid use of the
standard FTA-200 test as a laboratory ad-
junct for the diagnosis of syphilis is the
capacity of certain scra to react with the anti-
gen (s) common to both pathogenic and sapro-
phytic treponemal strains. Deacon (1) in-
vestigated 4 treponemal strains including Trep-
onema pallioTum and the Reiter's treponeme
and found a common antigen to all. Reactivity
to the common antigen has been regarded as
non-specific for syphilis, and Hunter et al. (2)
proposed a solution to the problem which en-
tailed selective combination of the antibody to
the common fraction with a liquid Reiter's
treponemal sonicate. Thus, emerged the FTA
absorbed test (FTA-ABS) * which was highly
selective for the Niehol's strain antigen(s)
without sacrificing sensitivity. Because the
Reiter's sonieate antigen as an absorbing agent
has not been completely evaluated and is not
yet available commercially, many laboratories
are still performing the FTA-200 test (3).
This report deals with certain conditions
which cause the FTA-200 procedure to become
moderate or strongly reactive, and which, though
non-specific for syphilis, have valuable clinical
significance; and if not properly understood,
may be mistaken as due to syphilitic infection.
Presented at the Twenty-sixth Annual Meeting
of The Society for lavestigative Dermatology,
Inc., New York, N.Y., June 21, 1965.
* From the Department of Clinical Laborato-
nes** and Department of Dermatology,*** Henry
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* Four types of FTA reactions are referred to
in this report:
FTA-200 Utilizes .%oo dilution pt. serum and
fluorescein conjugated anti-human
globulin (Ref. 3)
FTA-ABIS Utilizes pt. serum diluted ¼ in Reiter
treponemal sonicate and fluorescein
conjugated anti-human globulin (Ref.
2)
FTA-M Utilizes 1/4 dilution pt. serum and is
modified to use fluorescein conjugated
anti-human gamma globulin. (Ref. 6,
F TA-MR An initially positive FTA-M test which
can be reversed by appropriate ab-
sorption.
The authors indicated in a preliminary short
report (4) that the FTA-200 test (actually an
FTA-M, although not referred to as such at
that time) became reactive with sera which
also produced nuclear immunofluorescence on
tumor imprints (5) presumably associated with
the anti-nuclear factors (ANF). We also demon-
strated that systemic lupus erythematosus pa-
tients and many suffering from other connective
tissue disorders also produced nuclear immuno-
fluorescence and a moderate to strong FTA-200
test result. We feel, therefore, that the reac-
tivity of the FTA-200, which was modified ac-
cording to Wilkinson (6, 7) by using goat
anti-human gamma globulin (FTA-M) in-
stead of anti-human globulin fluorescein con-
jugate, represents detection of a type of trep-
onemal antibody, and though non-specific for
syphilis, tends to indicate a disorder of the con-
nective tissue type.
MATERIALS AND METHODS
Sera producing the non-syphilitic type FTA re-
action were absorbed with whole human malignant
tumor homogenate, whole tumor cell nuclei, tumor
cytoplasmic residue, tumor nuclear sonicate and
Reiter's treponemal sonicate.5 Tumors included
malignant melanoma, rhabdomyosareoma, renal
cell carcinoma, osteogenic sarcoma and neuro-
blastoma. Absorptions were performed at 4—7° C.
for one hour and at 37° C. for 15, 30 and 60 min-
utes, and the absorbed sera were tested once again
by the FTA modified (FTA-M) procedure and
the tumor imprint technic for anti-nuclear factors.
Tumor homogenates were prepared by grinding
in a glass tissue mortar as described previously
(4). Tumor nuclei were separated (8, 9) by minc-
ing the tissue obtained surgically or from autopsy
specimens and homogenizing it at maximum speed
in a Waring blendor 6 minutes in 1 per cent citric
acid (10 ml per gm wet weight of tissue). Certain
tumors required longer homogenization, but never
more than 12 minutes total time. The homogenate
was poured through layered cheesecloth to remove
gross particles, and nuclei were recovered by dif-
ferential centrifugation and washed three times in
0.2 per cent citric acid. Nuclei were stored in 02
* Obtained through the courtesy of Difco Lab-
oratories, Detroit, Michigan.
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per cent citric acid at 40 C. and re-suspended in
veronal buffered saline, pH 7.4 for sonic lysis and
direct absorption use. A suspension containing
11,400 nuclei/cu mm was sonicated 18—20 [Cc/sec.
for 8 minutes in an ice bath by a Mullard MSD
ultrasonic disintegrator.*
Sera to be absorbed were mixed with an equal
volume of whole nuclei suspension, packed cen-
trifugally with supernatant removed or were di-
luted ½ using the nuclear sonicate. Absorptions
using the tumor homogenates or cytoplasmic resi-
due were performed by mixing equal volumes of
serum and absorbant, incubating appropriately and
removing the supernatant following centrifugation.
All sera so treated were regarded as having an
initial ½ dilution. These were diluted an addi-
tional Meo to produce the final ØI used for the
FTA-M procedure. Sera were diluted ¼ using a
Reiter sonicate according to the method of Hunter,
e( ol. (2).
Fluorcsccin conjugated anti-human globulin
serum and anti-human gamma globulin serum
(goat) were titrated according to U.S.P.H.S. (3)
recommendations ageinst a strongly reactive syph-
ilitic serum to determine what dilution produced
a 4+ reaction. Non-reactive, 2+ and 4+ control
sera were run.
Slides were viewed on a Leitz Ortholux binocu-
lar microscope with a 540>< oil immersion objec-
tive illuminated by an Osram HBO 200 lamp, BC
12 excitation filter and a combination 0G4 and
CC4 pair, 1 mm thickness each as barrier filters.
RESULTS
Fifty seven patients had a reactive FTA-M
test, and 45 of these also had a positive nuclear-
immunofluoresccnt reaction. These patients were
considered non-syphilitic, and the medical diag-
noses are shown in Table I. Routine serologic
tests tended to be negative and are tabulated in
Table II. Twenty-two or 49 per cent of these
were lupus erythematosus patients, and these,
combined with the rheumatoid arthritis, sclero-
derma and the numbers of suspected connective
tissue disorders, comprised 82 per cent of the
group. Use of Reiter's sonicate to absorb these
sera before re-testing resulted in 13 of 18 be-
coming PTA negative, as shown in Table V.
None of these became anti-nuclear factor nega-
tive following Reiter's sonicate absorption. It was
thought initially that Reiter's sonicate removed
some fraction from the serum, leaving a brilliant
though altered pattern of nuclear immunofluo-
rescence upon the tumor cell imprints. However,
continued investigation of this finding revealed
that the altered pattern of fluorescence on the
* Courtesy of Parke, Davis and Company, De-
troit, Michigan.
TABLE I
Diagnostic categories—Reactive FTA -M
(57 Patients)
Reactive ANF
(Non-syphilitic)
45 patients
Non-Reactive ANF
(Possible syphilitic pattern)
12 patients
22 Lupus erythemato- 1 Lupus erythcmatosus
sus 1 Sclerodcrma
6 Suspected connec- 1 Rheumatoid arthritis
tive tissue disorder 1 Psoriasis
5 Scleroderma 1 Codeine, Demerol
4 Rheumatoid arthri- seositivity
tis 7 No conclusion
2 Vasculitis
1 Epileptic
1 Aortitis
1 Dermatomyositis
1 Jessner's lympho-
cytic infiltrate
1 Hydralazine syn-
drome
1 psychoneurosis
tumor imprint was probably due more to dilution
(1/5) than to removal of antibody fraction be-
cause, essentially, the same type of altered fluo-
rescence was seen in 1/5 serum-saline controls.
Thirty five probable non-syphilitic scm pro-
duced a negative FTA-M, and 29 of these
produced a positive anti-nuclear factor result
(Table III). Six of 29 (21 per cent) were lupus
crythematosus patients, and combined with
rheumatoid arthritis and scleroderma patients
gave a total of 13 (45 per cent) of connective
tissue disorders that did not produce a positive
FTA-M test. The serologic results are tabulated
in Table IV.
Use of whole human tumor homogenate as
an absorbing agent resulted in 8 of 28 sera
becoming negative to the FTA-M, ic. FTA-MR,
test and 12 which became reduced (Table V).
In earlier work, we reported finding that with
a single lot the Reiter's sonicate was slightly
less active in removing the antibody than the
tumor homogenates, but subsequent work using
other lots of the sonicate showed the trend
consistently reversed. Sonicate absorptions were
more consistent and more complete than the
whole tumor homogenate absorptions. The tumor
homogenate absorptions usually resulted in
removal or alteration of anti-nuclear factor
activity (Table V). Tumors for absorption
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TABLE II
Serologic data—Reactive PTA -M
(57 Patients)
Reactive ANF
(Non-syphilitic)
45 patients
Non-Reactive ANF
(Possible syphilitic pattern)
12 patients
NR*
WR
R
NP
VDRL
31
6
2
6
25
2
7
11
RPCF
28
L
8
8
NR
WR
R
NP
VDRL
3
5
4
0
4
0
6
2
RPCF
4
1
7
0
* NR—Non-reactive
WR—Weakly reactive
R—Reactive
NP—Not performed
TABLE III
Diagnostic categories—Non-Reactive PTA -M
(Probable Non-syphilitic)
(35 Patients)
Reactive ANF
29 Patients
Non-Reactive ANF
5 Patients
6 Lupus erythematosus 3 Hepatitis
4 Rheumatoid arthritis 3 No conclusion
3 Scleroderma
1 Malignant disease
1 Light eruption
1 Myopathy
1 Rheumatic fever
1 Ecrematous dermatitis
1 Ulcerative colitis
1 Anemia
1 Myasthenia gravis
1 Polymyositis
1 Pyelonephritis
1 Ulcers (Vasculitis)
5 No conclusion
seemed to be about equally efficacious when
freshly prepared, and they remained active for
approximately three months as stored homoge-
nates. Lyophilization of tumor homogenate fol-
lowed by storage for periods exceeding a year
resulted in loss of absorbing capacity.
Too few sera (12) from this group of 45 were
absorbed with cytoplasmic residue to draw def-
inite conclusions, but the trend was toward a
reduction of the anti-nuclear factor result
while leaving the FTA-M result variable. Cyto-
plasmic absorption was about as efficient as
tumor homogenate absorption in reversing the
reactive FTA-M result (Table V).
On a limited number of specimens (12) the
sonicate of tumor cell nuclei was found superior
to whole suspended nuclei as an absorbing
agent. The nuclear sonicate was used to dilute
sera 1/5 as with the Reiter's sonicate. The
nuclear sonicate either did not alter the fluores-
cent brilliance of the original FTA test or
served to increase it, while it usually removed
the anti-nuclear type of immunofluorescence
upon tumor cell imprints, thus establishing that
a different fraction in the serum was responsible
for each of the two reactions (Figure 1).
Absorptions performed at 37°C. for 30 min-
utes were found to be slightly more effective
than those performed at 4—7° C.
TABLE IV
Serologic data—Non-Reactive PTA -M
(Probable non-syphilitic)
(35 Patients)
Reactive ANF
29 Patients
Non-Reactive ANF
6 Patients
NR
WR
R
NP
VDRL
16
3
2
8
5
0
4
20
RPCF
11
0
5
13
NH
WR
H
NP
VDRL
4
1
1
0
5
0
0
1
RPCF
6
0
0
0
TABLE V
Absorption data—Reactive PTA -M, Reactive ANP
(Non-syphilitic)
(45 Patients)
FTA result
Reiter
suni-
cate
Tumor
hsmng-
enate
c t -n Nuclei
Nochange
SI. change (FTA-MR)
Marked change (FTA-MR)
NP
1
4
13
27
6
4
0
35
8
12
8
17
1
5
6
33
2
6
4
33
1
1
6
37
8
4
0
33
2
2
6
35
ANE result
Nochange
SI. change
Marked change
NP
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Pie. 1
Certain sera from this group of 45 patients
produced a peculiar type of immunofluores-
cence in the original unabsorhed FTA-M test
result which made the treponeme appear as
though gaps or holes were present in the
fluorescent antibody coating. This same finding
was called to our attention by another labora-
tory after testing some of our scra. From the
appearance of the fluorescence, we referred to
this as the "moth-eaten effect." It was not a
consistent finding with scra suspected of having
come from connective tissue disorders, and we
have been unable to photograph the effect
properly.
Use of the fiuoresccin labelled anti-human total
globulin resulted in FTA-200 reactions which
were always weaker than those produced by
the modified procedure (FTA-M) using anti-
human gamma globulin (10). Substitution of
fluorescein tagged anti-human B2M (macro) -
globulin (11) for the tagged anti-human gamma
globulin gave universally negative test rc-
salts. This particular conjugate was used be-
cause certain sera from the group were found
by gel immunoclectrophoresis* to have an ele-
vated B,M globulin fraction (12). Significance
of this finding is currently under investigation.
Continued investigation of the relationship
between brilliance of the FTA-M fluorescence
and intensity of nuclear fluorescence has demon-
strated no close parallel, contrary to our original
report. However, the parallelism of reactivity was
corroborated.
A known syphilitic group comprised of 27
patients constituted the controls for this study.
It will be noticed in Table VI that none of
the syphilitic patients had positive antinuclear
factor tests. The serologic data included 2 with
non-reactive FTA-M tests. Because of previous
experience with the types of reactions produced
by known syphilitics, only six were selected
randomly for absorptions, and these showed
* Courtesy of C. A. LoGrippo, M.D., Henry
Ford Hospital.
IMPRINTED TUMOR
CELl.
ANTI-NUCLEAR FACTOR
POSITIVE SERUM
ANTI-S MAY BE ABLE
TO CROSS REACT WITH
REITERS PROTEIN
ALTHOUGH flOP IS HR
INDICATING POSSIBILITY®
NIC ISO L'S
TREPONEMA PALLIDUM
TIC SERUM
I REITERS ANTIBODY
I PALLIDUM ANTIBODY
HYPOTHETICAL MULTIPLE ANTIBODY REACTION
BETWEEN ANTINUCLEAR FACTOR(S) AND NICHOLS
TREPONEM E
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TABLE VI
Serologic data
(Known syphilitics)
(27 Patients)
ANF
NR27
WR 0
R 0
FTA-M
NR 2
14 25
NR
WIt
R
NP
VDRL
0
9
18
0
Kolmer
4
0
21
2
RPCF
3
3
21
0
TABLE VII
Absorption data—Reactive FTA -M,
Non-Reactive AK?
(Syphilis or possible syphilis)
(27 Patients)
FTA result
NoChange
Sl. Change (FTA-MR)
Marked Change (FTA-
MR)
NP
Reiter Tumor
soni- homog-
rate enate
4 3
2 3
0 0
21 21
clsm Nuclei
2 5
3 0
0 0
22 22
essentially no change or only slight change to
any of the absorbing agents (Table VII).
Normal serum controls were negative to the
FTA-M procedure at the 1/4 or 1/5 use dilu-
tions of fluorescein isothiocyanate conjugated
anti-human gamma globulin sera.
DISCUSSION
Apparently, at least two antibodies are con-
tained in sera which produce respectively the
PTA-MR reactions and nuclear immunofluores-
cent reactions upon tumor imprints. The evi-
dence points to the fact that the fraction which
reacts with the Niehol's treponeme to produce
the modified PTA is probably directed against
the cytoplasm of the tumor imprint and
therefore is different from the fraction(s) which
cause(s) the anti-nuclear type of immunofluores-
cenee for the following reasons: The Reiter's
sonieate removes the fraction which produces
the PTA fluorescence, but leaves the anti-nu-
clear fluorescence undiminished. The tumor
homogenate which contains nuclear and eyto-
plasmie material rendered the PTA negative or
significantly diminished, and it reduced all anti-
nuclear reactions to faint fluorescence except
two. Tumor nuclear absorption tended to re-
move the anti-nuclear factor from sera, and
yet it either resulted in an unchanged or
brighter PTA result. We have no explanation
for this increase in brilliance which frequently
accompanies nuclear absorption except to hy-
pothesize that it may remove a partially block-
ing type of antibody. The eytoplasmie residue
partially diminished the PTA brilliance and ren-
dered the anti-nuclear fluorescence negative or
variable. Some of the variability of the cyto-
plasmic absorption may be explained by the
fact that these preparations were contaminated
with tumor cell nuclei, and where the anti-
nuclear factor reactions became diminished, it
was probably due to such contamination.
In no case did we see cytoplasmie fluorescence
on the tumor imprints. This may be attrib-
uted to masking the eytoplasmie reactivity
by use of rhodamine isothioeyanate tagged
bovine albumin as a counterstain. Without
the eounterstain, the entire tumor cell in the
imprints appeared to fluoresce, making accurate
anti-nuclear factor determinations difficult or
impossible. Alternatively, the responsible eyto-
plasmie antigens may be dissolved away during
the staining procedure.
We found one rheumatoid arthritis patient
with a negative anti-nuclear factor test result
and an PTA-MR reaction, thereby establishing
that the two results could not have been due to
the same antibody in this case. This individual
had no clinical evidence of syphilis, and his
serologic battery included a non-reactive VDRL,
Kolmer and RPCP. This is further evidence
that the anti-eytoplasmic factor probably pro-
duces the non-syphilitic type of PTA reaction.
The PTA-MR reaction occurring simultane-
ously with the nuclear immunofluoreseenee
seems to have no correlation with the intensity
and type of nuclear fluorescence pattern seen,
i.e., homogeneous, speckling, etc. This consti-
tutes further evidence that the PTA-MR reac-
tion is not due to anti-nuclear factor but to
some other associated antigen-antibody system,
perhaps against eytoplasmie antigens.
Based upon these data, the two antibodies
involved in these reactions might be as follows:
(See Pigure 1) One, an anti-cytoplasmie anti-
dody, (anti-B) probably reacts with an antigen
B common to the spirochete and (tumor) cell
cytoplasm. Cytoplasmie antigen B may or may
not be identical with a Reiter's antigen R. This
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common identity would explain the reversibility
of the FTA-M in these sera after Reiter's soni-
eate absorption. However, the fact that the
RPCF test is usually negative upon sera
producing the reactive PTA and ANP tests
(Table II) serves to east some doubt about the
role of the Reiter's antigen in these reactions.
The second antibody (anti-A), the anti-nuclear
factor, appears only to react with nuclear ma-
terial, antigen A, and does not seem to be
responsible for the reversible modified PTA.
(FTA-MR)
It should be noted that from within the
group which had a positive anti-nuclear fac-
tor test result and an PTA-MR reaction, the
greatest number of diagnoses were lupus erythe-
matosus or other confirmed or suspected con-
nective tissue disorders (Table I). A report of a
modified reversible FTA test (FTA-MR) should
be accorded much more clinical significance
than merely a report of a negative PTA-200
because it provides excellent evidence of a bio-
logical false positive reaction for syphilis (13,
14) and suggests very strongly the presence of
an auto-immune disorder. In true sypbilitics,
the FTA-M results are not reversible; the
anti-nuclear test is usually negative, and no
such indication of an auto-immune process
exists.
Based upon the evidence presented, the
authors feel that the FTA-200 procedure modi-
fied by use of anti-human gamma globulin should
continue to be performed as an adjunct to the
diagnosis of connective tissue diseases, even in
the advent of the PTA absorbed test (FTA-
ABS) which is more specific for syphilis. The
FTA has its greatest value in diagnostic situa-
tions where patients manifest problematic sero-
logic reactions, some of which could be due to
an auto-immune disorder. Thus, it would appear
to be preferable to use the PTA-M followed
by absorption rather than perform the PTA-
ABS only. This would make certain that clues
to a connective tissue disorder would not be lost
by the PTA-ABS procedure which does not
have provision for readings before and after
absorption. Disorders such as lupus erythema-
tosus and rheumatoid arthritis often produce a
positive PTA-M test which is reversible (FTA-
MR), and such a procedure seems to provide
additional evidence toward the diagnosis of such
processes.
Routine use of the PTA-MR as an additional
screening test for auto-immune disorders is
suggested.
SUMMARY
Two distinct antibodies appear to be respon-
sible respectively for tbe simultaneous occurrence
of anti-nuclear factor and modified PTA-200
(PTA-M) reactions from scra of patients having
certain connective tissue disorders, notably
lupus erythematosus. The positive modified
PTA (PTA-M) reaction was reversible by ab-
sorption with Reiter's trcponemal sonicate,
whole human tumor homogenate absorption and
partially reversible with human tumor cyto-
plasmic residue. Human tumor cell nuclear
sonicate either rendered no PTA absorption or
resulted in increased fluorescent brilliance. The
antibody responsible for the reversible modified
PTA (PTA-MR) result is thought to be the
same as a factor capable of reacting with tumor
cell cytoplasm. Syphilitic antibodies cannot be
absorbed from their respective scra by the meth-
ods described here.
Use of the PTA modified reversible (PTA-
MR) reaction as an additional screening test for
auto-immune processes is advocated.
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